Non-Cochrane · prognostic · PM41562911
Computational Stemness and Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma: A Systematic Review, Dual Meta-Analysis, and Functional Meta-Synthesis.
Ardila Carlos M, Pineda-Vélez Eliana, Vivares-Builes Anny M · Medical sciences (Basel, Switzerland) · 2025 · PubMed · doi:10.3390/medsci14010021
Findings
Population Adults with histologically confirmed oral squamous cell carcinoma
4 findings
| High computational stemness signature or risk score (mRNAsi, lncRNA, multigene, CpG signatures) | Low stemness signature or risk score | Overall survival Main analysis (k = 6) | HR 2.24 [1.61, 3.12] Moderate Downgraded: risk of bias, imprecision, inconsistency 6 studies |
| High computational stemness signature or risk score (mRNAsi, lncRNA, multigene, CpG signatures) | Low stemness signature or risk score | Overall survival Sensitivity: excluding Shi et al. (KM-derived unadjusted HR) (k = 5) | HR 2.13 [1.56, 2.89] GRADE not reported 5 studies |
| CSC-positive immunophenotype by tissue immunohistochemistry (CD44, CD133, xCT/SLC7A11) | CSC-negative or low immunophenotype | Overall survival Main analysis (k = 2) | HR 2.01 [1.42, 2.84] Low Downgraded: risk of bias, imprecision, inconsistency 2 studies |
| CSC-positive immunophenotype by tissue immunohistochemistry (CD44, CD133, xCT/SLC7A11) | CSC-negative or low immunophenotype | Overall survival Exploratory sensitivity: adding Ortiz et al. 1-year HR (k = 3) | HR 0.77 [0.16, 3.81] GRADE not reported 3 studies |
Included primary studies 20
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Feng 2021 Characterization of Cancer Stem Cell Characteristics and Development of a Prognostic Stemness Index Cell-Related Signature in Oral… DOI:10.1155/2021/1571421 | 2021 | this review only | Overall survival | not extracted yet |
| Feng 2021 Characterization of Cancer Stem Cell Characteristics and Development of a Prognostic Stemness Index Cell-Related Signature in Oral… PMID:34840626 | 2021 | this review only | Overall survival | not extracted yet |
| Gotz 2018 ALDH1 as a prognostic marker for lymph node metastasis in OSCC DOI:10.3892/br.2018.1131 | 2018 | this review only | not stated | not extracted yet |
| Gotz 2018 ALDH1 as a prognostic marker for lymph node metastasis in OSCC. PMID:30233780 | 2018 | this review only | not stated | not extracted yet |
| Lee 2018 Overexpression of cysteine‐glutamate transporter and CD44 for prediction of recurrence and survival in patients with oral cavity squamous… DOI:10.1002/hed.25331 | 2018 | this review only | Overall survival | not extracted yet |
| Lee 2018 Overexpression of cysteine-glutamate transporter and CD44 for prediction of recurrence and survival in patients with oral cavity squamous… PMID:30303590 | 2018 | this review only | Overall survival | not extracted yet |
| Lohavanichbutr 2013 A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation DOI:10.1158/1078-0432.ccr-12-2647 | 2013 | this review only | Overall survival | not extracted yet |
| Lohavanichbutr 2013 A 13-gene signature prognostic of HPV-negative OSCC: discovery and external validation. PMID:23319825 | 2013 | this review only | Overall survival | not extracted yet |
| Oliveira 2014 CD44+/CD133+ immunophenotype and matrix metalloproteinase-9: Influence on prognosis in early-stage oral squamous cell carcinoma. PMID:24178866 | 2014 | this review only | Overall survival | not extracted yet |
| Ortiz 2024 CSChighE-cadherinlow immunohistochemistry panel predicts poor prognosis in oral squamous cell carcinoma DOI:10.1038/s41598-024-55594-5 | 2024 | this review only | Overall survival | not extracted yet |
| Ortiz 2024 CSChighE-cadherinlow immunohistochemistry panel predicts poor prognosis in oral squamous cell carcinoma. PMID:38719848 | 2024 | this review only | Overall survival | not extracted yet |
| Rao 2020 Prognostic Significance of ALDH1, Bmi1, and OCT4 Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma DOI:10.1177/1073274820904959 | 2020 | this review only | not stated | not extracted yet |
| Rao 2020 Prognostic Significance of ALDH1, Bmi1, and OCT4 Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. PMID:32951453 | 2020 | this review only | not stated | not extracted yet |
| Shen 2017 Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma DOI:10.1186/s13148-017-0392-9 | 2017 | this review only | Overall survival | not extracted yet |
| Shen 2017 Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma. PMID:28852427 | 2017 | this review only | Overall survival | not extracted yet |
| Shi 2024 Identification and Validation of a Prognostic Signature Derived from the Cancer Stem Cells for Oral Squamous Cell Carcinoma DOI:10.3390/ijms25021031 | 2024 | this review only | Overall survival | not extracted yet |
| Shi 2024 Identification and Validation of a Prognostic Signature Derived from the Cancer Stem Cells for Oral Squamous Cell Carcinoma. PMID:38256104 | 2024 | this review only | Overall survival | not extracted yet |
| Xu 2022 Development of a lncRNA-based prognostic signature for oral squamous cell carcinoma. PMID:35100473 | 2022 | this review only | Overall survival | not extracted yet |
| Yu 2022 Identification and Validation of HOTAIRM1 as a Novel Biomarker for Oral Squamous Cell Carcinoma DOI:10.3389/fbioe.2021.798584 | 2022 | this review only | Overall survival | not extracted yet |
| Yu 2022 Identification and Validation of HOTAIRM1 as a Novel Biomarker for Oral Squamous Cell Carcinoma. PMID:35087800 | 2021 | this review only | Overall survival | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adults with histologically confirmed OSCC | Adults with OSCC (11 studies) |
| Intervention | Computational stemness models from omic data; CSC immunomarkers by IHC | Computational stemness signatures (n=6 studies); CSC-IHC markers (n=3 studies, 2 pooled; 2 further narrative only) |
| Comparison | High vs low stemness risk or biomarker expression by study-defined thresholds | High vs low stemness/risk; CSC-positive vs negative |
| Outcomes | Overall survival (primary); disease-specific and recurrence-free survival (secondary) | Overall survival pooled (6 computational; 2 CSC-IHC); DSS/RFS not pooled |
| Study designs | Human cohort studies (retrospective or prospective), including public OSCC dataset analyses | Cohort studies; 11 included, 9 in meta-analysis |
| Timing | Not specified | Not specified |